Uncategorized
Allergan reports Q3 financial results
Allergan plc reported its continuing operations performance for the third quarter of 2016, including total net revenues of $3.6 billion, a 4% increase compared with the prior year quarter.Strong performance from key brands in eye care, aesthetics, plastic surgery and skin care, and new product launches helped the revenues for the quarter. Revenues were offset by the loss of Asacol HD exclusivity, lower revenues for Namenda XR and IR, and unfavorable foreign exchange impact, according to a press release.